Clinical Trial Update: Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of bendamustine hydrochloride, etoposide, dexamethasone, and filgrastim for peripheral blood stem cell mobilization in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Etoposide (Etoposide)
• Neupogen (Filgrastim)
• Treanda (Bendamustine)

Snippet

Sponsor: University of Washington | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24